Please upgrade your browser.
Cell-Cycle Gene Test Shows Early Promise in Clear Cell RCC - See more at: http://www.onclive.com/conference-coverage/aua-2014/Cell-Cycle-Gene-Test-Shows-Early-Promise-in-Clear-Cell-RCC#sthash.DhoRovxs
A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology...
Nearly half of respondents report losing access to doctors, hospitals, and treatments
Prof Swanton discusses his presentation at the recent European International Kidney Cancer Symposium sponsored by US based Kidney Cancer Association
Madison-based biotech firm Centrose received a six-month $224,734 grant...
Patients with metastatic renal cell carcinoma face a poor prognosis; currently, 30% of patients already have metastatic disease at the time of diagnosis, according to national data.
"The strategy of repurposing drugs that are currently being used for other indications is of significant interest to the medical community..."
Prof Wood talks to ecancertv at the EIKCS conference about the different surgical strategies available for approaching renal cell carcinoma with inferior vena cava invasion and their outcomes post-surgery.
Results for nivolumab and Yervoy® (ipilimumab) as a combination regimen in three tumor types to be presented, including melanoma and the first findings in non-small cell lung cancer and renal cell carcinoma.
Global Clinical Trials Review, H1, 2014" provides data on the Papillary Renal Cell Carcinoma clinical trial scenario.
Resistance to these agents develops frequently, and their use is often limited by intolerance.
|Powered by NeonCRM|